{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT01506843",
      "orgStudyIdInfo": {
        "id": "F3046"
      },
      "secondaryIdInfos": [
        {
          "id": "CNPq",
          "type": "OTHER_GRANT",
          "domain": "CNPq480010/2007-2"
        }
      ],
      "organization": {
        "fullName": "Federal University of Uberlandia",
        "class": "OTHER"
      },
      "briefTitle": "Sublingual Immunotherapy in Children With Allergic Rhinitis",
      "officialTitle": "Clinical Efficacy and Mucosal/Systemic Antibody Response Changes After Sublingual Immunotherapy in Mite-allergic Children in a Randomized Double-blind, Placebo-controlled Study in Brazil",
      "acronym": "SLIT"
    },
    "statusModule": {
      "statusVerifiedDate": "2007-08",
      "overallStatus": "COMPLETED",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2008-10"
      },
      "primaryCompletionDateStruct": {
        "date": "2010-10",
        "type": "ACTUAL"
      },
      "completionDateStruct": {
        "date": "2011-04",
        "type": "ACTUAL"
      },
      "studyFirstSubmitDate": "2011-12-20",
      "studyFirstSubmitQcDate": "2012-01-09",
      "studyFirstPostDateStruct": {
        "date": "2012-01-10",
        "type": "ESTIMATED"
      },
      "lastUpdateSubmitDate": "2012-01-09",
      "lastUpdatePostDateStruct": {
        "date": "2012-01-10",
        "type": "ESTIMATED"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "PRINCIPAL_INVESTIGATOR",
        "investigatorFullName": "Ernesto Akio Taketomi",
        "investigatorTitle": "Principal Investigator",
        "investigatorAffiliation": "Federal University of Uberlandia"
      },
      "leadSponsor": {
        "name": "Federal University of Uberlandia",
        "class": "OTHER"
      },
      "collaborators": [
        {
          "name": "Conselho Nacional de Desenvolvimento Científico e Tecnológico",
          "class": "OTHER_GOV"
        }
      ]
    },
    "oversightModule": {
      "oversightHasDmc": true
    },
    "descriptionModule": {
      "briefSummary": "The purpose of this study is to evaluate the clinical efficacy and mucosal/systemic antibody response changes after SLIT using house dust mite allergen with or without bacterial extracts in mite-allergic children.",
      "detailedDescription": "Patients with allergic rhinitis with or without asthma were selected for a randomized double-blind, placebo-controlled trial and distributed into three groups: DPT (Dpt allergen extract, n=34), DPT+MRB (Dpt allergen plus mixed respiratory bacterial extracts, n=36), and Placebo (n=32). Clinical evaluation and immunological analyses are being carried out before and after 12 and 18 months of treatment, including rhinitis/asthma symptom and medication scores, skin prick test (SPT) to Dpt, and measurements of Dpt-, Der p 1-, Der p 2-specific serum IgE, IgG4, IgG1 and -specific salivary IgA."
    },
    "conditionsModule": {
      "conditions": [
        "Allergic Rhinitis"
      ],
      "keywords": [
        "IgA antibody",
        "IgE antibody",
        "IgG1/IgG4 subclasses",
        "Mite allergy",
        "Sublingual immunotherapy",
        "Saliva"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "designInfo": {
        "allocation": "RANDOMIZED",
        "interventionModel": "FACTORIAL",
        "primaryPurpose": "TREATMENT",
        "maskingInfo": {
          "masking": "QUADRUPLE",
          "whoMasked": [
            "PARTICIPANT",
            "CARE_PROVIDER",
            "INVESTIGATOR",
            "OUTCOMES_ASSESSOR"
          ]
        }
      },
      "enrollmentInfo": {
        "count": 122,
        "type": "ACTUAL"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "mite allergen drop",
          "type": "ACTIVE_COMPARATOR",
          "description": "Children with allergic rhinitis sensitized with dust mites will receive progressive doses of allergen drops comparing those receiving placebo.",
          "interventionNames": [
            "Biological: Mite, Mite and Bacterial or Placebo"
          ]
        },
        {
          "label": "mite plus bacterial extracts",
          "type": "ACTIVE_COMPARATOR",
          "description": "Vaccine constituted with mite and bacterial extracts will be compared to placebo.",
          "interventionNames": [
            "Biological: Mite, Mite and Bacterial or Placebo"
          ]
        },
        {
          "label": "Placebo",
          "type": "PLACEBO_COMPARATOR",
          "description": "Placebo will be constituted by the same solution used to make dilution of the allergen extracts.",
          "interventionNames": [
            "Biological: Mite, Mite and Bacterial or Placebo"
          ]
        }
      ],
      "interventions": [
        {
          "type": "BIOLOGICAL",
          "name": "Mite, Mite and Bacterial or Placebo",
          "description": "All treatments were given by sublingual route according to schedule of EAACI, with some modification. Patients received up-dosing sublingual drops once a day, reaching in approximately 3 months a monthly maintenance dose of 36 μg of Der p 1 given three times a week in alternate days for mite, mite and bacterial allergen extract, and no Der p 1 and no bacterial components in the placebo group. Doses were delivered by using vials equipped with a metered-dose dropper, and subjects were instructed to hold the solution under the tongue for 2 min and not to eat or drink for 60 min after the dose. Subjects self-administered the treatment at home. Adjustments in the schedule were made on an individual basis according to standard guidelines for specific immunotherapy",
          "armGroupLabels": [
            "Placebo",
            "mite allergen drop",
            "mite plus bacterial extracts"
          ],
          "otherNames": [
            "mite allergen extract",
            "bacterial allergen extract"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Change from Baseline in Symptom and Medication Scores at 12 months",
          "description": "For clinical evaluation will be used a questionnaire determining the symptom and medication scores.",
          "timeFrame": "Baseline and 12 months"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "Change from Baseline in Specific Antibody Levels.",
          "description": "Measurement of serum specific antibodies (IgE, IgG1, IgG4, and IgA) to Dermatophagoides pteronyssinus total extract, and Der p 1 and Der p 2 allergens.",
          "timeFrame": "Baseline, 12 months and 18 Months"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n* Clinical diagnosis of allergic rhinitis\n* Positive skin test to Dermatophagoides pteronyssinus total extract\n* Positive serum levels of specific IgE to D. pteronyssinus extract\n\nExclusion Criteria:\n\n* Previous allergen immunotherapy\n* Use of antihistamines 1 week or topical corticosteroid up to 3 weeks prior to skin prick test\n* Long term use of systemic corticosteroid.\n* Airway infection 30 days prior to the selection.\n* Children with severe asthma, malignant, cardiovascular or autoimmune diseases, under chemotherapy or immunosuppressor therapy.\n* Users of cigarette smoke\n* Presence of severe skin lesions",
      "healthyVolunteers": false,
      "sex": "ALL",
      "minimumAge": "5 Years",
      "maximumAge": "15 Years",
      "stdAges": [
        "CHILD"
      ]
    },
    "contactsLocationsModule": {
      "overallOfficials": [
        {
          "name": "Ernesto A Taketomi, MD, PhD",
          "affiliation": "Federal University of Uberlandia",
          "role": "PRINCIPAL_INVESTIGATOR"
        }
      ],
      "locations": [
        {
          "facility": "Asthma and Rhinitis Control Program",
          "city": "Itumbiara",
          "state": "Goiás",
          "zip": "75503-520",
          "country": "Brazil",
          "geoPoint": {
            "lat": -18.41917,
            "lon": -49.21528
          }
        }
      ]
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2026-02-04",
      "submissionTracking": {
        "estimatedResultsFirstSubmitDate": "2012-01-09",
        "submissionInfos": [
          {
            "releaseDate": "2012-01-09",
            "resetDate": "2012-02-08"
          }
        ]
      }
    },
    "conditionBrowseModule": {
      "meshes": [
        {
          "id": "D065631",
          "term": "Rhinitis, Allergic"
        }
      ],
      "ancestors": [
        {
          "id": "D012220",
          "term": "Rhinitis"
        },
        {
          "id": "D009668",
          "term": "Nose Diseases"
        },
        {
          "id": "D012140",
          "term": "Respiratory Tract Diseases"
        },
        {
          "id": "D012130",
          "term": "Respiratory Hypersensitivity"
        },
        {
          "id": "D010038",
          "term": "Otorhinolaryngologic Diseases"
        },
        {
          "id": "D006969",
          "term": "Hypersensitivity, Immediate"
        },
        {
          "id": "D006967",
          "term": "Hypersensitivity"
        },
        {
          "id": "D007154",
          "term": "Immune System Diseases"
        }
      ]
    }
  },
  "hasResults": false
}